4.7 Letter

Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer

期刊

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
卷 322, 期 12, 页码 1209-1211

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2019.10650

关键词

-

资金

  1. Conquer Cancer Foundation from the National Cancer Institute of the National Institutes of Health [5-T32-CA009615, K23-CA187185]

向作者/读者索取更多资源

This research letter discusses the association between label restrictions by the US Food and Drug Administration on first-line immunotherapy for advanced bladder cancer and subsequent changes in practice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据